Phase 1 N=3 Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Brain Neoplasms, Primary Malignant
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=19 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Phase 1 N=127 Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness — 0; 0; 1; 5 Participants
Phase 1 N=13 Barre Exercise in Parkinson's
Parkinson Disease
Primary: Attendance — 10 Participants
Phase 1 N=51 Study of V117957 in Overactive Bladder Syndrome
Overactive Bladder Syndrome
Primary: Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours. — -0.8; -0.8; -0.2; -0.4 Episodes per 24 hours
Phase 1 N=62 MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
Advanced or Metastatic Breast Cancer
Primary: MTD of MEN1611 in Combination With Trastuzumab ± Fulvestrant — 48 milligrams (mg)
Phase 1 N=61 Combination HTNV and PUUV DNA Vaccine
Hantaan Virus Disease, Puumala Virus
Primary: Summary of Solicited Local Adverse Events (AEs) — 8; 11; 12; 9 Participants
Phase 1 N=81 Remote Mindfulness Training Following Early Life Adversity
Stress · Mindfulness · Early Life Adversity
Primary: Feasibility of Recruitment (Screened Eligible) — 81; 56; 112; 642 Participants
Phase 1 N=11 Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
Phase 1 N=32 Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients With Dose Limiting Toxicities (DLT) - Part A — 0; 0 Participants
Phase 1 N=23 A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Phase 1 N=133 This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Neoplasms · Breast Neoplasms
Primary: [Cohort A, B, C & D] Maximum Tolerated Dose (MTD) of Xentuzumab — 1000; 1000; 1000; 1000 milligram
Phase 1 N=12 A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Becker Muscular Dystrophy
Primary: Percentage of Participants Treated With Sevasemten Experiencing AEs — 100 percentage of participants
Phase 1 N=7 Valacyclovir in Neonatal Herpes Simplex Virus Disease
Neonatal Herpes Simplex Infection
Primary: Area Under the Curve Following Administration of Oral Valacyclovir Suspension 20 mg/kg Every 8 Hours — 28.8 mgxh/l
Phase 1 N=21 Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Xentuzumab in Japanese Patients With Advanced Solid Tumours, as Identified by the Number of Patients With Dose-limiting Toxicities (DLTs)…